OncoMatch/Clinical Trials/NCT06572618
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
Is NCT06572618 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Rituximab and Nemtabrutinib for mantle cell lymphoma.
Treatment: Nemtabrutinib · Rituximab — This phase II trial tests how well nemtabrutinib works with rituximab for the treatment of patients with mantle cell lymphoma. Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nemtabrutinib with rituximab may kill more cancer cells in patients with mantle cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Without bone marrow involvement: ANC ≥ 1,000/mm^3; with bone marrow involvement: ANC ≥ 500/mm^3; Without bone marrow involvement: platelets ≥ 75,000/mm^3; with bone marrow involvement: platelets ≥ 30,000/mm^3
Kidney function
Serum creatinine ≤ 1.5 × ULN OR creatinine clearance of ≥ 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 1.5 × ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels > 1.5 × ULN; AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN
Cardiac function
Corrected QT (QTc) prolongation (QTcF > 450 msecs) or other significant ECG abnormalities including second degree AV block type II, third degree AV block, or bradycardia (ventricular rate < 50 beats/min) [excluded]
Without bone marrow involvement: ANC ≥ 1,000/mm^3, with bone marrow involvement: ANC ≥ 500/mm^3; Without bone marrow involvement: platelets ≥ 75,000/mm^3 with bone marrow involvement: platelets ≥ 30,000/mm^3; Total bilirubin ≤ 1.5 × ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels > 1.5 × ULN; AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN; Serum creatinine ≤ 1.5 × ULN OR creatinine clearance of ≥ 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula; Corrected QT (QTc) prolongation (QTcF > 450 msecs) or other significant ECG abnormalities including second degree AV block type II, third degree AV block, or bradycardia (ventricular rate < 50 beats/min) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
- City of Hope at Irvine Lennar · Irvine, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify